Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)-Reference-Cited by-同舟云学术

Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)

Published:2016-05 Issue: Volume:141 Page:S5-S8
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Santagostino Elena

Publisher

Elsevier BV

Subject

Hematology

Reference12 articles.

1. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX;Metzner;Thromb Haemost,2009

2. Half-life extension through albumin fusion technologies;Schulte;Thromb Res,2009

3. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients;Santagostino;Blood,2012

4. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients;Martinowitz;Haemophilia,2015

5. ClinicalTrials.gov. A safety and efficacy study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B. https://clinicaltrials.gov/ct2/show/NCT01496274. Accessed 14 January 2016.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications;Theranostics;2024

2. Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity;British Journal of Haematology;2021-06-09

3. Prospects for the use of prolonged concentrates of blood clotting factor IX in the treatment of hemophilia B;Russian Journal of Pediatric Hematology and Oncology;2021-01-07

4. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo;mAbs;2021-01-01

5. Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry;Iraqi Journal of Hematology;2021